January 2009
Worldwide Biotech;Jan2009, Vol. 21 Issue 1, p6
Trade Publication
The article reports on the contract awarded by Public Works and Government Services Canada to Bavarian Nordic in January 2009 for the delivery of Imvamune, a Modified Vaccinia Ankara (MVA)-based, third generation smallpox vaccine. As stated, the procurement will be used by the Canadian authorities as part of the nation's bio-preparedness program. Details of the contract include the provision of optional purchase of an additional 180,000 doses of the vaccine. Also noted are the features of the drug.


Related Articles

  • HHS Ordering 20 Million Doses Of Bavarian Nordic's Imvamune. Boggs, Jennifer // BioWorld Today;4/17/2007, Vol. 18 Issue 74, p1 

    The article reports on the plan of the U.S. Department of Health and Human Services to buy 20 million doses of the Imvamune vaccine from Bavarian Nordic A/S. It might be the first contract award under the U.S. RFP-3, a request for proposals for modified vaccinia ankara (MVA)-based vaccine for...

  • Bavarian's Smallpox Vaccine Pact Worth Up To $1.6 Billion. Sheridan, Cormac // BioWorld International;6/6/2007, Vol. 12 Issue 23, p1 

    The article reports on the contract won by Bavarian Nordic A/S to supply a stockpile of next-generation safe smallpox vaccines to the U.S. Department of Health and Human Services. The pharmaceutical company is expected to earn a total of $1.6 billion from the contract. The vaccine produced by...

  • Bavarian Lands $545M Deal For Smallpox Vaccine Stockpile. Sheridan, Cormac // BioWorld International;4/18/2007, Vol. 12 Issue 16, p1 

    The article announces that Bavarian Nordic A/S is poised to land a contract to supply the U.S. government with a stockpile of 20 million doses of its next-generation smallpox vaccine Imvamune. The value of the deal is mentioned. Bavarian Nordic's rival company is Acambis plc. Comments from Rolf...

  • US extends Imvamune smallpox vaccine trials.  // PharmaWatch: Biotechnology;Dec2007, Vol. 6 Issue 12, p4 

    The article reports on the extension of an existing contract provided by the U.S. government with Bavarian Nordic AS to include a larger Phase II study with Imvamune. The drug is the company's investigational smallpox vaccine for persons diagnosed with atopic dermatitis. According to the report,...

  • Battling Bioterror.  // Pharmaceutical Executive;Oct2004, Vol. 24 Issue 10, p21 

    Reports on a contract awarded by the United States government to Acambis and Bavarian Nordic to develop and produce a Modified Vaccinia Ankara smallpox vaccine. Value of the deal; Reduction of complications in the weaker version of the vaccine.

  • Danish Biopharma Company Secures $500-Million U.S. Contract. Scott, Alex // Chemical Week;6/20/2007, Vol. 169 Issue 21, p31 

    The article highlights the announcement of the U.S. Department of Health and Human Services (HHS) that it had agreed to contract out the manufacture of 20 million doses of smallpox vaccine to biopharmaceutical company Bavarian Nordic for $500 million. The value of the groundbreaking deal could...

  • NEWS IN BRIEF. Tyler, Alan // European Chemical News;10/11/2004, Vol. 81 Issue 2119, p28 

    Presents news briefs on the fine chemicals industry as of October 11, 2004. Value of the contract awarded by the U.S. National Institutes of Health to Bavarian Nordic for the development of a smallpox vaccine; Implication of a new grade of carbon nanofibre developed by Japanese firm Showa Denko...

  • OTHER NEWS TO NOTE.  // BioWorld International;11/26/2008, Vol. 13 Issue 48, p2 

    This section offers news briefs on the biotechnology industries. Asterand plc has completed a placement of 4.3 million shares at 15 pence each. Bavarian Nordic A/S received a $25 million milestone payment from the U.S. government by submitting safety data from a Phase II trial of smallpox...

  • Production of smallpox vaccine approved.  // Pharmaceutical Technology Europe;Nov2006, Vol. 18 Issue 11, p14 

    The article reports on the approval of the production facility of Bavarian Nordic AS in Kvistgard, Denmark by the Danish Medicines Agency. After the authorization, the company could start to operate as a large-scale commercial production of smallpox vaccine. On the other hand, the company...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics